Studies have confirmed that apatinib can not only inhibit tumor growth by blocking neovascularization but also directly act on SCLC cells with high expression of VEGFR2, and inhibit tumor growth by promoting apoptosis and inducing cell cycle arrest. Here, KDR is linked to small cell lung carcinoma.